News Sobi plans filings for gout drug after phase 3 readout SEL-212 will compete with Horizon's fast-growing Krystexxa if approved by the FDA.
News Gilead presses go on first Nurix protein degrader drug Opt-in for IRAK4 drug comes after a Kymera/Sanofi candidate showed early activity in trials.
News Double blow for Sangamo as Novartis, Biogen exit deals The two deals for gene-modifying candidates were worth up to $3.1 billion including milestones.
News Could Daiichi Sankyo have another ADC winner in cancer? New data point to impressive efficacy in advanced EGFR-mutated non-small cell lung cancer.
News Chasing BMS, Takeda trumpets TYK2 data in psoriasis Pharma group is hoping for big things, after splashing out $4bn upfront for the drug last year.
News AbbVie’s Skyrizi hits the spot in refractory psoriasis Antibody works when IL-17 inhibitors Like Novartis' Cosentyx and Lilly's Taltz fail.
News Lilly partners with Hims & Hers on obesity drug sales Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies sold directly on the telehealth company's platform.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
